Novo Nordisk : NVO

All Novo Nordisk Articles

168 Articles

Rich Duprey | Feb 25, 2025 at 12:41 PM EST

HIMS Stock Craters – Is It a Buying Opportunity?

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said…

Rich Duprey | Feb 24, 2025 at 12:36 PM EST

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO | NVO…

Ian Cooper | Feb 21, 2025 at 11:47 AM EST

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is…

Trey Thoelcke | Feb 14, 2025 at 8:45 AM EST

AbbVie Just Paid Investors: Here’s How Much They Received

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50…

Joey Frenette | Jan 23, 2025 at 12:01 PM EST

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After…

Omor Ibne Ehsan | Jan 22, 2025 at 11:15 AM EST

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Eli Lilly (NYSE: LLY | LLY Price Prediction) doesn’t really need much of an introduction. It has become a household…

Rich Duprey | Jan 21, 2025 at 3:15 PM EST

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has been described as the best pure-play stock in artificial intelligence. The market…

Rich Duprey | Jan 15, 2025 at 9:06 AM EST

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly…

Omor Ibne Ehsan | Dec 17, 2024 at 8:58 AM EST

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

The Dow Jones is one of Wall Street’s most iconic benchmarks and it tracks 30 of America’s largest companies. It…

Will Ashworth | Nov 7, 2024 at 11:12 AM EST

These 3 Stocks Are Winning Thanks to Baby Boomers

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or…

Rich Duprey | Oct 3, 2024 at 7:53 PM EDT

Is John Paulson’s Best Investment Ever a Buy or Sell

The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the…

Trey Thoelcke | Sep 19, 2024 at 9:15 AM EDT

Prediction: This Will Be the Biggest Pharma Stock in 10 Years

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are…

Rich Duprey | Sep 14, 2024 at 11:42 AM EDT

Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell

Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money”…

Ian Cooper | Sep 12, 2024 at 11:50 AM EDT

Five Top Obesity Stocks to Buy and Hold Long Term

Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX…

Joey Frenette | Sep 11, 2024 at 2:40 PM EDT

2 Weight Loss Drug Stocks Worth Stashing Away for Years

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to…

1 … 4 5 6 7 8 … 12

Novo Nordisk : NVO

All Novo Nordisk Articles

HIMS Stock Craters – Is It a Buying Opportunity?

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

AbbVie Just Paid Investors: Here’s How Much They Received

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

These 3 Stocks Are Winning Thanks to Baby Boomers

Is John Paulson’s Best Investment Ever a Buy or Sell

Prediction: This Will Be the Biggest Pharma Stock in 10 Years

Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell

Five Top Obesity Stocks to Buy and Hold Long Term

2 Weight Loss Drug Stocks Worth Stashing Away for Years

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here’s How to Retire There at 62 Without Touching Your Savings

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here's How to Retire There at 62 Without Touching Your Savings

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

Novo Nordisk : NVO

All Novo Nordisk Articles

HIMS Stock Craters – Is It a Buying Opportunity?

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

AbbVie Just Paid Investors: Here’s How Much They Received

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

These 3 Stocks Are Winning Thanks to Baby Boomers

Is John Paulson’s Best Investment Ever a Buy or Sell

Prediction: This Will Be the Biggest Pharma Stock in 10 Years

Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell

Five Top Obesity Stocks to Buy and Hold Long Term

2 Weight Loss Drug Stocks Worth Stashing Away for Years

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here’s How to Retire There at 62 Without Touching Your Savings

Featured Reads

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here's How to Retire There at 62 Without Touching Your Savings